The National Cancer Act 20 years later: impact as seen by its architects in 1991

Community sites have the patients to boost trial enrollment—but not the infrastructure

I have spent over 20 years running a tumor imaging metrics core at an academic cancer center. In that time, I have watched clinical trial enrollment concentrate at a relatively small number of flagship academic institutions. Unfortunately, trials do not propagate well to the community sites where most patients prefer to receive care. The explanations usually offered for why this happens have never fully accounted for what I observed.

Philip Castle named NCI associate director for prevention

Philip E. Castle was appointed NCI associate director for prevention.

November 06, 2026

Vol.52 No.41

Clinical Roundup

CRC incidence rates are rising among all age groups, SEER data analysis finds

Rising incidence of colorectal cancer now extends beyond younger adults to nearly all age groups, according to a study analyzing the most recent data from NCI to examine incidence rates of colorectal cancer over a 20-year period.

November 06, 2026

Vol.52 No.41

NCI

NCI’s new CCSG is the result of “thousands of hours” of listening, negotiations, surprises
New NOFO aims to shrink applications by 40%

Late next month, NCI is expected to publish the new criteria it uses to bestow designations on America’s network of cancer centers.

NCAB ad hoc working group seeks to define its role as it approves eight reissue concepts
“We could do a lot more than be another committee to check the RFAs before they go to the next level.”

Members of the National Cancer Advisory Board’s ad hoc Working Group on Extramural Research Concepts and Programs at a recent meeting struggled to define the new group’s the role and raised concerns about some initial growing pains.

October 30, 2026

Vol.52 No.40

By Jacquelyn Cobb

Cancer History Project

Facing stage 4 cholangiocarcinoma, Keaton Herzer moved mountains to take off-label therapy, get a transplant
Two years later, he has no evidence of disease

Keaton Herzer had never even heard of cholangiocarcinoma when he was diagnosed in 2025.

October 30, 2026

Vol.52 No.40

By Deborah Doroshow and Sara Willa Ernst

The National Cancer Act 20 years later: impact as seen by its architects in 1991

YOU MAY BE INTERESTED IN

Community sites have the patients to boost trial enrollment—but not the infrastructure

Philip Castle named NCI associate director for prevention

CRC incidence rates are rising among all age groups, SEER data analysis finds

NCI’s new CCSG is the result of “thousands of hours” of listening, negotiations, surprises
New NOFO aims to shrink applications by 40%

NCAB ad hoc working group seeks to define its role as it approves eight reissue concepts
“We could do a lot more than be another committee to check the RFAs before they go to the next level.”

Facing stage 4 cholangiocarcinoma, Keaton Herzer moved mountains to take off-label therapy, get a transplant
Two years later, he has no evidence of disease

Renew today!

Subscriber content

Never miss an issue!

Login

The National Cancer Act 20 years later: impact as seen by its architects in 1991

YOU MAY BE INTERESTED IN

Community sites have the patients to boost trial enrollment—but not the infrastructure

Philip Castle named NCI associate director for prevention

CRC incidence rates are rising among all age groups, SEER data analysis finds

NCI’s new CCSG is the result of “thousands of hours” of listening, negotiations, surprisesNew NOFO aims to shrink applications by 40%

NCAB ad hoc working group seeks to define its role as it approves eight reissue concepts“We could do a lot more than be another committee to check the RFAs before they go to the next level.”

Facing stage 4 cholangiocarcinoma, Keaton Herzer moved mountains to take off-label therapy, get a transplantTwo years later, he has no evidence of disease

Never miss an issue!

Login

NCI’s new CCSG is the result of “thousands of hours” of listening, negotiations, surprises
New NOFO aims to shrink applications by 40%

NCAB ad hoc working group seeks to define its role as it approves eight reissue concepts
“We could do a lot more than be another committee to check the RFAs before they go to the next level.”

Facing stage 4 cholangiocarcinoma, Keaton Herzer moved mountains to take off-label therapy, get a transplant
Two years later, he has no evidence of disease